MONOPAR THERAPEUTICS INC (MNPR)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for rare diseases like Wilson disease.
What MONOPAR THERAPEUTICS INC does
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutic and imaging agents, with primary emphasis on copper-chelating therapies and radiopharmaceutical technologies. The company's lead program is ALXN1840, a copper chelator for Wilson disease, which completed a pivotal Phase 3 trial meeting its primary endpoint, though the original developer (Alexion/AstraZeneca) terminated the program and Monopar is now assembling a regulatory package for NDA submission. The company is also advancing radiopharmaceutical programs for cancer imaging and treatment, though these face technical challenges including radioisotope supply constraints and novelty-related adoption risks.
Themes: rare diseases, oncology / cancer therapy, radiopharmaceuticals, clinical-stage biotech
Fundamentals
- Price$107.72 as of 2026-08-21 close
- Market cap$723M as of 2026-08-21
- 1-year return+238.3% 2025-08-21 close $31.84 → 2026-08-21 close $107.72
- P/En/a earnings data not available
- ROE-12.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.42 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How MNPR compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MONOPAR THERAPEUTICS INC looks technically
MONOPAR THERAPEUTICS INC (MNPR) is trading 45.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 45.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +45.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $100.73 | $100.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $74.13 | $74.13 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 124.82. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal | 30 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($105.42 to $124.82) — its "stochastic" reading is 12 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 11.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $124.82 | $124.82 |
|---|---|---|
| From the 52-week high | it is 13.7% below its 52-week high (its highest price of the past year) | -13.7% |
| Above the 52-week low | it is 269.2% above its 52-week low (its lowest price of the past year) | +269.2% |
| Below the 52-week high | it is 13.7% below its highest point of the past year | 13.7% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $240.00 (set on 2019-12-20) | $240.00 |
| Given back of the 52-week move | over the past year its closes ranged ($30.42 to $123.84), and it has given back roughly a quarter of its rise from last year’s low — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $63.12 to $66.11. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.3% |
| From the all-time high | it is 55.1% below its all-time high | -55.1% |
| Nearest price level | it is trading 2.9% above a support level at $104.58 — a price it turned at three times since 2025-10-06, most recently on 2026-08-03. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $1.37 (set on 2023-11-27) | $1.37 |
| Above the all-time low | it is 7762.8% above its all-time low | +7,763% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.46 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.46 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $105.03 and $123.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $105.03 – $114.29 – $123.54 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
| Stretch from the 200-day average | it is trading 4.5 daily ranges above its 200-day average price (45.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 8.1% since the prior reading | +8.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 3.4% above the previous close 44 sessions ago and has not traded back through the level it left behind at 64.39 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.4% |
| Gap filled | a 4.1% gap down opened on 2026-08-13 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -13.02% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.5 percentage points (the stock lost 5.2% while the market gained 2.3%) | -7.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 68.8 percentage points (the stock gained 71.9% while the market gained 3.1%) | +68.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 83.3 percentage points (the stock gained 94.4% while the market gained 11.1%) | +83.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 217.8 percentage points (the stock gained 238.3% while the market gained 20.5%) | +217.8% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 16% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +16.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 42% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $75.71 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +42.3% |
|---|
Price levels it has turned at before
MNPR last closed at $107.72 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $104.58 | Support | 2.9% below the last close | turned there three times · 2025-10-06 to 2026-08-03 |
| $100.75 | Support | 6.5% below the last close | turned there twice · 2025-11-24 to 2026-07-23 |
| $89.78 | Support | 16.6% below the last close | turned there twice · 2025-10-30 to 2025-11-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $124.82.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.46 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$126.31 range $100.00 – $145.00; median $128.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MNPR
- Consensus EPS estimate-$0.8367 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant financial losses with no currently approved products on the market.","Heavy reliance on raising additional capital for clinical trials, regulatory processes, and operations.","Uncertainties regarding regulatory approval, clinical trial success, and the novelty of radiopharmaceutical technology."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for MNPR — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding MNPR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 463,767
- Reported value $25,409,792
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MNPR had 1,065,108 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MNPR had 15.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.4 days to cover at the same settlement.
- Reported short interest (shares) 1,065,108
- Short interest (% of shares outstanding) 15.9%
- Prior settlement (shares) 1,360,286
- Reported change -21.7%
- Days to cover (reported) 3.4
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AstraZeneca (AZN)
- Novartis (NVS)
- RayzeBio (acquired by BMS)
- Telix Pharmaceuticals
- Perspective Therapeutics (CATX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MNPR vs…
MONOPAR THERAPEUTICS INC is found in…
Frequently asked questions
What does MONOPAR THERAPEUTICS INC (MNPR) do?
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutic and imaging agents, with primary emphasis on copper-chelating therapies and radiopharmaceutical technologies. The company's lead program is ALXN1840, a copper chelator for Wilson disease, which completed a pivotal Phase 3 trial meeting its primary endpoint, though the original developer (Alexion/AstraZeneca) terminated the program and Monopar is now assembling a regulatory package for NDA…
What sector is MONOPAR THERAPEUTICS INC (MNPR) in?
MONOPAR THERAPEUTICS INC (MNPR) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals. It trades on NASDAQ.
Who are MONOPAR THERAPEUTICS INC's (MNPR) competitors?
Notable peers of MONOPAR THERAPEUTICS INC (MNPR) include AstraZeneca, Novartis, RayzeBio (acquired by BMS), Telix Pharmaceuticals and Perspective Therapeutics. This peer set is informational only — not financial advice.
Is MONOPAR THERAPEUTICS INC (MNPR) overbought or oversold right now?
MONOPAR THERAPEUTICS INC (MNPR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MNPR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.